Establishment Labs reports Q4 EPS ($1.19), consensus (66c)

Reports Q4 revenue $44.5M, consensus $44.5M. “The approval of Motiva implants in the United States was a watershed moment for our company,” said Juan Jose Chacon-Quiros, Founder and Chief Executive Officer. “The interest from both plastic surgeons and patients has exceeded our expectations. In the fourth quarter, we had $3.3 million in sales in the United States – and momentum continues to build. We expect approximately $5.5 million in first quarter U.S. revenue, and at this tempo we should be able to meet and even exceed our $35 million guidance for the U.S. in 2025. We continue to aggressively manage our expenses, with our EBITDA loss improving almost $19 million this year over last despite the significant step up in our U.S. commercial efforts and investments in our organic innovation pipeline,” Mr. Chacon-Quiros continued. “We are targeting our first positive EBITDA quarter this year as well as turning cash flow positive next year. Our launch into the United States positions us for sustained growth and profitability. We are poised to become the global market leader with technologies that can remake and expand the breast aesthetics and reconstruction markets.”